HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On...
Hence then, the article about ascletis announces oral and poster presentations on asc47 an adipose targeted muscle preserving weight loss drug candidate for obesity at the 32nd european congress on obesity was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity )
Also on site :
- Thursday: What races the AP has not yet called in contests for Senate and governor
- What to Expect From Best Buy's Black Friday and Cyber Monday Sales This Year
- LEGO’s 2026 Holiday Ad Stars Daft Punk, E.T. & ‘KPop Demon Hunters’: Shop the Sets Featured in the Video